Brief: Revance Therapeutics Q1 Product Revenue USD 51.719 Million
09/05/2024 21:06
May 09 (Reuters) - Revance Therapeutics Q1 net income USD -53.152 million. * Q1 operating expenses USD 98.763 million
Recent news on Revance Therapeutics
See all newsBrief: Crown Laboratories and Revance Therapeutics Announce Expiration of Tender Offer
Brief: Crown Laboratories And Revance Amend A&R Merger Agreement
Deals of the day-Mergers and acquisitions
U.S. STOCKS ON THE MOVE-Kratos, Forward Air, Bank stocks
U.S. STOCKS ON THE MOVE-Henry Schein, natgas firms, Citigroup